Arcus Biosciences, Inc. Tax Withholding Paid on Stock Awards
Arcus Biosciences, Inc. (RCUS) reported Tax Withholding Paid on Stock Awards of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation · last filed 2026-02-25
- Arcus Biosciences, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Arcus Biosciences, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Arcus Biosciences, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2024-12-31 was $5.00M.
- Arcus Biosciences, Inc. payment, tax withholding, share-based payment arrangement for the quarter ending 2024-09-30 was $1.00M.
- Arcus Biosciences, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Arcus Biosciences, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2024 was $7.00M.
- Arcus Biosciences, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2023 was $0.00.
- Arcus Biosciences, Inc. payment, tax withholding, share-based payment arrangement for fiscal 2022 was $0.00.
| Period end | Payment, Tax Withholding, Share-based Payment Arrangement 3 month | Payment, Tax Withholding, Share-based Payment Arrangement 6 month | Payment, Tax Withholding, Share-based Payment Arrangement 9 month | Payment, Tax Withholding, Share-based Payment Arrangement 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $0.00 10-Q · filed 2025-10-28 | ||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | |||
| 2024-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.00M derived: sum of 2 quarters · filed 2026-02-25 | $7.00M 10-K · filed 2026-02-25 | |
| 2024-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-28 | $2.00M 10-Q · filed 2025-10-28 | ||
| 2024-06-30 | $1.00M 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | $0.00 10-K · filed 2026-02-25 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |